All In Biotech

NDA 020204 · Bayer

Aleve

Naproxen Sodium · Oral

Last checked: Nov 20, 2026Latest source record: Mar 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1994

Jan 11, 1994

Approved uses

1

Original approval plus efficacy supplements

Registered trials

356

90 Phase 3, 11 recruiting

FAERS reports

67,356

27,436 serious, 5,059 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 3, 2026.

Uses temporarily relieves minor aches and pains due to: minor pain of arthritis muscular aches backache menstrual cramps headache toothache the common cold temporarily reduces fever

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ALEVE · NAPROXEN SODIUM 220MG · TABLET, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Naproxen" as an intervention, any sponsor and status, largest first.

All 356 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective11,391
  • fatigue5,094
  • product use issue4,817
  • pain4,764
  • nausea4,287
  • arthralgia4,100
  • headache4,070
  • off label use4,008
  • dizziness3,972
  • diarrhoea3,952
  • rash3,569
  • vomiting3,471

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004644
2005773
2006633
2007659
20083,280
20091,851
2010786
20111,013
20121,808
20131,672
20143,782
20157,074
20166,846
20175,779
20184,953
20194,818
20203,673
20213,063
20222,961
20232,839
20243,552
20253,270
20261,625

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,373 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.